Skip Navigation LinksNBS-Disorders-Detectable

Newborn Screening program

California Expands Screening for Newborn Disorders. The California Newborn Screening (NBS) Program now includes screening for Guanidinoacetate Methyltransferase (GAMT) and Mucopolysaccharidosis Type 2 (MPS 2).ā€‹ā€‹

Disorders Detectable by Newborn Screening

The California Newborn Screening (NBS) Program provides newborn screening to all California babies for all of the core disorders listed on the Recommended Uniform Screening Panel (RUSP).

The RUSP is a list of disorders that are screened at birth and recommended by the Secretary of the Department of Health and Human Services for states to screen as part of their state universal newborn screening programs.

As of October 2020, the following RUSP disorders are screened for in California:

Core conditions are the conditions that newborn screening is specifically designed to identify.

GAMT and MPS II added to NBS in 2024

ā€‹Guanidinoacetate Methyltransferase (GAMT)
ā€‹Mucopolysaccharidosis Type II (MPS II)

ā€‹Guanidinoacetate Methyltransā€‹ferase (GAMT) deficiency is a rare condition that affects approximately 1 in every 275,000 births in the United States. GAMT deficiency occurs from a lack of the enzyme needed to convert guanidinoacetate into creatine. This enzymatic deficiency leads to an inability to store and use energy properly, resulting in brain, muscle, and behavior issues, along with developmental delays. 

Symptoms of GAMT deficiency typically appear between 3 months to 3 years of age.

Treatments for GAMT include supplements and medications. Other supportive care can include nutritional, speech, occupational, and behavioral therapies.

GAMT Resources

ā€‹Mucopolysaccharidosis Type II (MPS II), also known as Hunter syndrome, is a condition almost exclusively affecting males, with a prevalence of approximately 1 in 100,000 to 170,000 male births. MPS II prevents the body from breakingā€‹ down certain sugars, leading to a range of issues including bone, muscle, heart, and lung problems, as well as developmental delays. 

MPS II has two forms with varying onset and severity of symptoms. The severe form often presents early in life, while in the less severe form, symā€‹ā€‹ptoms may not appear until later in childhood.

Enzyme replacement therapy and sometimes stem cell transplant may be recomā€‹mended as treatment for MPS II. There are also new treatments being studied that may be available in the future.ā€‹

MPS II Reā€‹sources


The following are disorders that can be detected in the differential diagnosis of a core disorder:

Secondary conditions are the genetic conditions that can be identified when looking for a core condition.  A condition on the newborn screening panel is classified as a ā€œsecondary conditionā€ if it is identified unintentionally when screening for one of the core conditions, or as a consequence of confirmatory testing for an out-of-range result of a core condition. ā€‹

Please note: due to biological variability of newborns and differences in detection rates for the various disorders in the newborn period, the California Newborn Screening Program will not identify all newborns with these conditions. While a positive screening result identifies newborns at an increased risk to justify a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. 

Health care providers should remain watchful for any sign or symptoms of these disorders in their patients. A newborn screening result should not be considered diagnostic, and cannot replace the individualized evaluation and diagnosis of an infant by a well-trained, knowledgeable health care provider.

See below for a list of RUSP disorders, with their definitions and links to helpful resources where available.ā€‹ā€‹ā€‹ā€‹ā€‹ā€‹ā€‹

Definitions and Resources

Page Last Updated :